Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 26;13(9):2096. doi: 10.3390/cancers13092096

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The cytotoxic CD56^dimCD16⁺/CD56^brightCD16⁻ NK-cell ratio during HR-NBL therapy. (a) The ratio of absolute CD56^dimCD16⁺ and CD56^brightCD16⁻ Trucount cell numbers is highly variable between patients and is decreased at diagnosis and during therapy of HR-NBL patients. Dx: n = 7, 1st N5/N6: n = 11, 2nd N5/N6: n = 10; 3rd N5/N6: n = 11, before HD: n = 7, start IT: n = 7, After IT Cycle 1–3: n = 10, After IT cycle 4–5: n = 8. The dotted line reflects the reference value of the cytotoxic NK-cell ratio of healthy individuals [22]. (b,c) In-depth monitoring of the fraction of CD56^dimCD16⁺ and CD56^brightCD16⁻ in two patients during the IT course shows an increase in cytotoxic (CD56^dimCD16⁺) NK-cell phenotype after IL-2-containing IT cycles. In patient 1, the ratio remains below the normal cytotoxic NK-cell ratio of 9, whereas the ratio of patient 1 reaches normal values after the first IL-2-containing IT cycle and is increased after the second IL-2-containing IT cycle. Red arrows indicate start of IL-2-containing therapy cycles.

The cytotoxic CD56^dimCD16⁺/CD56^brightCD16⁻ NK-cell ratio during HR-NBL therapy. (a) The ratio of absolute CD56^dimCD16⁺ and CD56^brightCD16⁻ Trucount cell numbers is highly variable between patients and is decreased at diagnosis and during therapy of HR-NBL patients. Dx: n = 7, 1st N5/N6: n = 11, 2nd N5/N6: n = 10; 3rd N5/N6: n = 11, before HD: n = 7, start IT: n = 7, After IT Cycle 1–3: n = 10, After IT cycle 4–5: n = 8. The dotted line reflects the reference value of the cytotoxic NK-cell ratio of healthy individuals [22]. (b,c) In-depth monitoring of the fraction of CD56^dimCD16⁺ and CD56^brightCD16⁻ in two patients during the IT course shows an increase in cytotoxic (CD56^dimCD16⁺) NK-cell phenotype after IL-2-containing IT cycles. In patient 1, the ratio remains below the normal cytotoxic NK-cell ratio of 9, whereas the ratio of patient 1 reaches normal values after the first IL-2-containing IT cycle and is increased after the second IL-2-containing IT cycle. Red arrows indicate start of IL-2-containing therapy cycles.